MYBL2 and prostate cancer: Assessments of the baseline protein expression levels of KDM5D and MYBL2 in a panel of prostate cancer cell lines (Fig. 2A) revealed the two cell lines with detectable KDM5D, LNCaP, and CWR22Rv1, had the lowest MYBL2 expression.